Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Rolfo C, et al. Among authors: araujo a. Adv Exp Med Biol. 2017;995:97-125. doi: 10.1007/978-3-319-53156-4_5. Adv Exp Med Biol. 2017. PMID: 28321814 Review.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study).
Janzic U, Maimon Rabinovich N, Shalata W, Kian W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G, Pluzanski A, Araujo A, Charpidou A, Daher S, Agbarya A. Janzic U, et al. Among authors: araujo a. Curr Oncol. 2024 Jul 30;31(8):4369-4381. doi: 10.3390/curroncol31080326. Curr Oncol. 2024. PMID: 39195309 Free PMC article.
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. Porta R, et al. Among authors: araujo a. Crit Rev Oncol Hematol. 2017 May;113:256-267. doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23. Crit Rev Oncol Hematol. 2017. PMID: 28427515 Review.
3,118 results